Based on the subgroup analyses results, pembrolizumab seemed to improve progression-free survival compared with the placebo progression-free survival benefits were observed regardless of the chemotherapy regimen. 5.6 months hazard ratio = 0.82), the median duration of progression-free survival was longer with pembrolizumab than with the placebo. 0014), and in the ITT population (7.5 vs. In patient groups with a CPS of at least 10 (9.7 vs. Patients were stratified by chemotherapy regimen, PD-L1 status, and whether they received prior treatment with the same class of chemotherapy in the neoadjuvant or adjuvant setting. The chemotherapy regimens included nab-paclitaxel, paclitaxel, and gemcitabine plus carboplatin. Their findings, which were presented during the virtual edition of the 2021 PER’s Miami Breast Cancer Conference (Abstract 22), further support pembrolizumab's addition to standard chemotherapy in this patient population.Ī total of 847 patients with a locally recurrent inoperable or metastatic disease were enrolled in the intention-to-treat (ITT) population they were randomly assigned in a 2:1 ratio to receive chemotherapy in combination with pembrolizumab (n = 566) or a placebo (n = 281). Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, and colleagues conducted additional efficacy analyses. Using the data from this phase III study, Hope S. In the KEYNOTE-355 trial, patients with metastatic triple-negative breast cancer who expressed PD-L1 with a Combined Positive Score (CPS) of at least 10 seemed to derive a progression-free survival benefit from first-line treatment with pembrolizumab plus chemotherapy versus chemotherapy alone. KEYNOTE-355 enrolled adult women with previously untreated locally recurrent or inoperable or metastatic triple-negative breast cancer who completed curative treatment more than 6 months before first disease recurrence.
KEYNOTE 355 UPDATE
KEYNOTE-355 Update on Pembrolizumab in Triple-Negative Breast Cancerīy: Julia Fiederlein Posted: Thursday, April 1, 2021 The KEYNOTE-355 results extend the benefits to the advanced breast cancer setting.
0 kommentar(er)
